Characteristic histopathologic features have been described in high-grade serous carcinoma associated with BRCA abnormalities (HGSC-BRCA), which are known to have relatively favorable clinical outcomes. The aim of this study was to evaluate the clinical significance of invasion patterns in metastatic HGSC-BRCA cases. Of the 37 cases of advanced-stage HGSC with known BRCA1 or BRCA2 germline mutation retrieved from our institutional files, 23 patients had a germline mutation of BRCA1 and 14 had a BRCA2 mutation. The pattern of invasion at metastatic sites was recorded and classified as a pushing pattern (either predominantly or exclusively), an exclusively micropapillary infiltrative pattern, or an infiltrative pattern composed of papillae, micropapillae, glands, and nests (mixed infiltrative pattern). Histologic evaluation of metastases was performed without knowledge of genotype or clinical outcome. Clinical data were abstracted from medical records. Median age was 56 years (range, 31 to 73 y). All patients presented at stage IIIC or IV and underwent complete surgical staging followed by chemotherapy. All 37 HGSC-BRCA cases showed either pushing pattern metastases (30; 81%) or infiltrative micropapillary metastases (7; 19%). No HGSC-BRCA case exhibited metastases composed solely of mixed infiltrative patterns. Among the 7 infiltrative micropapillary cases, 6 had a BRCA1 germline mutation versus 1 with a BRCA2 mutation. The median time of follow-up was 26 months (range, 13 to 49 mo). All 7 patients with infiltrative micropapillary metastases either experienced recurrence or died of disease (5 recurrences and 2 deaths), which was significantly worse than what was seen in patients with predominantly pushing pattern metastases, of whom 16 of 30 (53%) experienced recurrence (n = 14) or died of disease (n = 2) (P = 0.03). In conclusion, the recognition of different invasion patterns of metastatic extrauterine HGSC-BRCA has prognostic implications. The infiltrative micropapillary pattern is associated with poor outcomes and is more frequently seen in BRCA1-associated HGSC than in BRCA2 cases.
H igh-grade serous carcinomas of the uterine adnexa with BRCA deficiency (HGSC-BRCA) have recently been described to demonstrate characteristic histopathologic features including solid, pseudoendometrioid, transitional cell-like growth patterns (SET pattern), high mitotic index, numerous tumor-infiltrating lymphocytes, and severe nuclear atypia. 1, 2 Our group has recently shown that HGSC-BRCA exhibits characteristic morphologic features in metastatic sites. Reyes and colleagues showed that all studied cases with BRCA1 or BRCA2 abnormalities showed either a pushing pattern of omental involvement (76% of cases) or a purely micropapillary infiltrative metastatic pattern (24% of cases). In contrast, all HGSC cases lacking BRCA alterations showed infiltrative metastases containing combinations of growth patterns including papillae, micropapillae, glands, and nests (a mixed infiltrative pattern). 3 HGSC-BRCA has been reported to be associated with relatively better clinical outcomes compared with HGSC without BRCA deficiency. This is partly because of increased sensitivity to chemotherapy and also possibly because of the tendency to spread in the form of circumscribed, rounded metastases amenable to optimal debulking. Furthermore, it has been reported recently that HGSC patients with a BRCA2 mutation have better survivals compared with BRCA1-mutated and BRCAnonmutated patients. [4] [5] [6] In this study, we hypothesize that the pattern of invasion at metastatic sites has clinical significance in patients with metastatic HGSC-BRCA.
MATERIALS AND METHODS
A total of 37 cases of advanced-stage HGSC with known BRCA1 or BRCA2 germline mutation were retrieved from the archives of the Department of Pathology at Memorial Sloan Kettering Cancer Center after obtaining institutional review board approval. These patients had undergone germline genetic testing as per the policies of the Gynecology Disease Management Team at Memorial Sloan Kettering Cancer, which strives to offer testing to all patients diagnosed with high-grade serous carcinoma of the peritoneum, ovary, and fallopian tube. Patient anonymity was maintained. These cases were accessioned between 2009 and 2012 and were exclusive of previously reported cases. 1, 3 Of 37 cases, 23 had a BRCA1 germline mutation and 14 had a BRCA2 germline mutation.
All patients presented at advanced stage (FIGO stage IIIC [n = 26] or IV [n = 11]) and underwent surgical staging followed by chemotherapy. All but two patients had undergone an optimal debulking surgery. A total of 19 patients were treated with intravenous and intraperitoneal chemotherapy, whereas the remaining 18 patients were treated only intravenously. Chemotherapy consisted of a platinum-containing agent and a taxane in all cases. All available hematoxylin and eosin slides from metastatic sites were reviewed. The median number of slides reviewed was 14, with a minimum of 3 slides. Diagnosis as HGSC was based upon Gilks' modification to the WHO criteria for diagnosing HGSC. 7 Gilks' modification classifies high-grade ovarian carcinomas as HGSC for cases showing solid, cribriform, microcystic, and transitional cell-like architectural patterns as long as confirmatory endometrioid features such as squamous metaplasia, endometrioid adenofibroma, associated endometriosis, and synchronous endometrioid carcinoma of the endometrium are absent. The presence of radially oriented slit-like spaces, scattered bizarre mononuclear giant cells, nuclear pleomorphism, and a high mitotic index are HGSC characteristics that are found at least focally in nearly every case.
Each metastatic site was evaluated for types of peritoneal invasion patterns. Two general patterns were distinguished: a pushing pattern ( Fig. 1 ), in which the interface between tumor and adipose tissue was rounded, linear, and/or smooth, and an infiltrative pattern ( Fig. 2) , which was characterized by irregular permeation of adipose tissue. Rules for distinguishing invasive and noninvasive implants of serous borderline tumor are similar. 8 The irregularly infiltrative patterns were further subdivided by architecture, with 1 pattern consisting of infiltrative micropapillae only ( Figs. 2A, B ) and another pattern showing infiltration by combinations of papillae and micropapillae and, in some cases, glands and solid tumor (mixed pattern; Fig. 2C ). 3 When different metastatic sites featured different patterns, the predominant pattern was recorded. In a hypothetical case containing 5 metastatic sites, a case was considered "pushing pattern" if 3, 4, or 5 metastatic sites displayed this pattern.
Tumor architectural growth patterns were also studied. Micropapillary tumor displayed dyshesive aggregates of tumor cells lacking central vascular cores surrounded by retraction space ( Figs. 2A, B ). Papillary architecture was defined as tumor cells arranged around finger-like vascular cores (Fig. 3A) . Solid architecture was defined as tumor cells arranged in sheets ( Fig. 3B ). Pseudoendometrioid (cribriform architecture) was defined as tumor growing in back-to-back nests with punched out microlumens ( Fig. 3C ). Transitional cell-like architecture was characterized by broad papillae with thick, stratified layers of tumor cells ( Fig. 3D ). Solid, pseudoendometrioid, and transitional cell-like growth patterns constituted the SET pattern (Figs. 3B-D).
Clinical data were abstracted from the medical records. Histologic evaluation of metastases was performed without knowledge of genotype or clinical outcome. Appropriate statistical tests were conducted.
RESULTS
The mean age of our cohort was 56 years (range, 32 to 76 y). The number of metastatic sites ranged from 1 to 10 and included the omentum, the serosa of the sigmoid, the appendix, the small bowel, the bladder, the gallbladder, the pelvic sidewall, the diaphragm, and the cul-de sac.
All 37 HGSC-BRCA cases showed either pushing pattern, defined by the predominant pattern found in cases with multiple metastatic sites, or infiltrative micropapillary metastases ( Fig. 4 ). Of the 37 cases, 30 demonstrated either an exclusive or predominant pushing pattern, whereas the remaining 7 cases exhibited only infiltrative micropapillary metastases. Of the 30 pushing pattern cases, 17 showed pushing patterns in each metastatic site (exclusively pushing pattern). Of the 17 exclusively pushing pattern cases, 14 exhibited a solid or transitional cell-like architectural component; 8 were purely solid or transitional cell-like; 4 had combinations of solid, papillary, micropapillary, and pseudoendometrioid patterns; and 2 had combinations of solid and papillary patterns. The remaining exclusively pushing pattern metastases were purely papillary (n = 1), purely glandular (n = 1), or mixed papillary and micropapillary (n = 1). Thirteen cases featured a predominance of pushing pattern metastases along with smaller numbers of destructively infiltrating metastases featuring combinations of solid, papillary, and micropapillary architecture (mixed pattern). In these 13 cases, the percentage of pushing pattern metastases among all metastases ranged from 57% to 80% (median, 67%). No case exhibited only mixed pattern metastases comprising papillae and micropapillae with or without solid, transitional cell-like, or pseudoendometrioid patterns. The mean age of patients with pushing pattern metastases was 56 years (range, 44 to 68 y), whereas those with infiltrative micropapillary metastases were, on average, 54 years old (range, 32 to 77 y), differences that were not statistically significant.
The distribution of invasion patterns and tumor architecture in metastatic sites, stratified by the genetic subgroup, is illustrated in Table 1 . Among the 23 BRCA1 germline mutation cases, 17 cases had pushing pattern metastases, showing, in decreasing frequency, solid, papillary, and pseudoendometrioid tumor architecture. Regarding the BRCA2 patients, pushing pattern metastases showing solid and papillary architecture were seen in all cases except 1. Overall, among the 7 infiltrating micropapillary cases, 6 had BRCA1 germline mutations versus 1 with a BRCA2 mutation, suggesting that infiltrating micropapillary cases are enriched for BRCA1 patients.
The median follow-up time was 26 months (range, 13 to 49 mo). All 7 patients with infiltrating micropapillary carcinoma either experienced recurrence or died of disease (5 recurrences and 2 deaths), which was significantly worse than that seen in patients with pushing pattern metastases, only 16 of 30 (53%) of whom experienced recurrence (n = 14) or died of disease (n = 2) (P = 0.03).
DISCUSSION
The data presented here validate previously reported associations between BRCA germline mutation and HGSCs with: (1) solid, pseudoendometrioid, and transitional cell-like growth patterns (SET pattern); and pushing pattern metastasis in the form of rounded tumor nodules lacking destructive invasion at their periphery. 3 Novel findings include the greater prevalence of metastatic HGSCs with pushing pattern metastases among BRCA2 mutation carriers as compared with BRCA1 mutation carriers. Only 1/14 BRCA2 metastases showed an exclusively micropapillary infiltrative pattern, compared with 6/23 BRCA1 germline cases. Lastly, we demonstrated that patients with pushing pattern metastases have significantly better clinical outcomes than do patients with destructively invasive metastases at a median follow-up of 26 months. Previously reported relationships between genomically defined subsets of HGSC 9 and morphology, platinum sensitivity, and clinical outcome suggest that our data could explain relatively favorable clinical outcomes in patients with "transitional cell carcinoma of ovary" 5 and/ or who carry BRCA germline mutations. 6 
Invasion Patterns and Clinical Outcomes in Gynecologic Carcinomas
The relationship between invasion patterns and clinical outcomes has been the subject of recent publications. With specific reference to gynecologic carcinomas, poor clinical outcomes or high-stage disease is reportedly associated with certain destructively invasive squamous carcinomas of the cervix 10 and with microcystic, elongated, and fragmented invasive endometrioid carcinoma. 11 Meanwhile, endometrioid adenocarcinomas that have a pushing pattern of invasion 12 and human papilloma virus-associated endocervical adenocarcinomas with a highly differentiated glandular pattern of invasion lacking a stromal response 13, 14 are reportedly associated with favorable clinical outcomes. It was also previously reported that many "transitional cell carcinomas" of the ovary metastasize to the peritoneum in the form of small, rounded nodules that are more amenable to surgical debulking than tumors showing other invasion patterns. 5 These tumors often display enhanced platinum sensitivity and relatively favorable clinical outcomes. There is a growing consensus that high-grade "transitional cell carcinomas" of the ovary [15] [16] [17] are HGSC variants, [18] [19] [20] and this is reflected in the 2014 World Health Organization classification of gynecologic tumors. 21 With respect to HGSC, Dr Elvio Silva's group reported an abstract in which patients with HGSCs showing invasion patterns similar to the infiltrative micropapillary pattern reported here had significantly worse clinical outcomes 
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Pushing pattern invasion (n=30) than did patients whose tumor lacked this invasion pattern. 22 
Correlations Between Genotype and Phenotype
There is also increasing interest in understanding the relationships between genotype and morphologic phenotype. Our group previously reported that many BRCA-associated HGSCs demonstrate "SET pattern" morphology along with numerous tumor-infiltrating lymphocytes; relationships between SET pattern morphology and pushing pattern metastasis were also described. 1, 3 The Brigham group recently validated these associations and expanded on them by linking the presence of SET-pattern architecture in the primary site with relatively favorable clinical outcomes. 23 This group also, intriguingly, hypothesized a dualistic model of high-grade serous carcinogenesis in BRCA1 mutation carriers, one arm of which is characterized by young age, low prevalence of serous tubal intraepithelial carcinoma, SET morphology, and favorable clinical outcomes. Indeed, we found 2 mutually exclusive patterns of peritoneal metastasis in BRCA1 germline mutation carriers, 1 with favorable outcomes (SET and either exclusively or predominantly pushing pattern metastases) and 1 with destructive invasion by micropapillae.
The Cancer Genome Analysis (TCGA) subclassified HGSCs into 4 genomically defined, mostly exclusive groups: immunoreactive, proliferative, differentiated, and mesenchymal. 9 The immunoreactive group harbored the most cases with germline BRCA mutation, best sensitivity to platinum-based chemotherapy, and most favorable clinical outcomes, whereas the mesenchymal group contained fewer cases with BRCA germline mutations; carcinomas in this category also featured platinum insensitivity and very poor clinical outcomes. As tumor cells were not microdissected, categorization as immunoreactive or mesenchymal must have derived, at least in part, from the tumor microenvironment. If this assertion is true, then the immunoreactive tumors would have large numbers of tumor-infiltrating immune cells, whereas the mesenchymal tumors would exhibit intermingling of tumor cells with host stroma. Although it was not clearly defined whether the case material was limited to tissue from the adnexa or metastatic sites, we speculate that "immunoreactive" tumors are closely aligned with SET pattern and pushing pattern metastasis, particularly those with many tumor-infiltrating lymphocytes, and that "mesenchymal" tumors are more likely to show destructive patterns of invasion that feature intermingling of epithelial cells and stroma, including infiltrative micropapillae. Along these lines, radiologists from our institution recently published the results of genomic-radiologic correlations that assert strong relationships between "immunoreactive" HGSCs and round peritoneal tumor nodules on one hand and between "mesenchymal" HGSCs and destructively infiltrative metastases that frequently involve the intestinal mesentery on the other. 24 Finally, the TCGA study concluded that incorporating HGSC group assignment along with BRCA status provides optimal outcome predictions. 9 The data presented here are similar to those of a different cohort reported previously by our group. 1, 3 The cohort of 102 HGSCs represented patients with the following: (1) sporadic HGSCs lacking BRCA abnormalities; (2) sporadic HGSCs with BRCA1 promoter methylation, somatic BRCA1 mutation, or somatic BRCA2 mutation; or (3) patients carrying a germline mutation in either BRCA1 or BRCA2. We reported that exclusively or predominantly pushing pattern metastases were confined to patients with BRCA1 or 2 aberration, whether or not the aberration was a germline mutation. Pushing pattern metastases were found in 76% of patients or tumors with a BRCA aberration, a figure similar to that reported here, whereas the remaining patients had micropapillary-only infiltrative metastases. With only rare exceptions, patients with pushing pattern metastases had their primary site tumor showing SET architecture. Patients whose tumors had intact BRCA had mixed pattern infiltrative metastases without any pushing pattern metastases or purely micropapillary infiltration. Although we did not assess the reproducibility of our criteria for classifying patterns of peritoneal metastasis in the current study, the previous study reported that only 2 cases were classified differently by 2 observers working independently, which suggests that our criteria are reproducible. 
